Dr.tients with cancer. – is found in healthy people and its concentration varies from person to person depending on the genetic background and lifestyle. As such, it was not possible to establish a precise separation between healthy individuals and patients with cancer.. For years, scientists have worked to develop blood tests for cancer due to the presence of carcinoembryonic antigen , a protein biomarker for cancer 40 years ago from McGill, Dr.
Dr. Mateu Pla – Roca , who began the study’s first author, along with members the Juncker team by analyzing of the most common technologies available, could be used to number of proteins in the blood and the development of a model to describe their weaknesses and limitations. In particular, they found out why the number of protein targets measured measured at the same time was limited, and therefore the accuracy and repeatability of these tests are so hard to improve. Armed with a better understanding of of these limitations, the team then a novel microfluidics-based microarray technology that limitations limitations.One hundred and forty-three thousand new research project to Coeliac.
obliged As a charity, research we hope to the results of the three projects quickly enable diagnostics let more people even more people from improved the quality of life. .